Exelixis (EXEL) Gross Profit Growth (5y) (2017 - 2026)

Exelixis (EXEL) Gross Profit Growth (5y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 18.11%
Jan 2, 2026 17.42%
Oct 3, 2025 21.10%
Jul 4, 2025 17.00%
Apr 4, 2025 19.77%
Sep 27, 2024 14.60%
Jun 28, 2024 21.63%
Mar 29, 2024 14.20%
Dec 29, 2023 15.66%
Sep 29, 2023 15.76%
Jun 30, 2023 20.21%
Mar 31, 2023 13.65%
Dec 30, 2022 28.63%
Sep 30, 2022 21.81%
Jul 1, 2022 33.43%
Apr 1, 2022 34.57%
Oct 1, 2021 39.58%
Jul 2, 2021 60.57%
Apr 2, 2021 98.15%
Oct 2, 2020 92.40%